Crown Prince Khaled bin Mohamed Steers UAE Toward Precision Medicine with Historic Genomic Initiative

A landmark masterplan will extend genome sequencing to all Emirati citizens and deliver personalised health insights to nearly a million participants, positioning the Emirates at the forefront of AI-powered healthcare.

The machinery of healthcare is shifting beneath us. Where once diagnosis meant waiting for illness to reveal itself, the future speaks in the language of prevention, in the quiet intelligence of genetic data analysed before symptoms emerge. This week, that future took tangible shape as H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, chaired a meeting of the Emirates Genome Council and endorsed the 2026-2028 National Genomics Masterplan, a blueprint that will reshape how the nation approaches health and wellbeing.

The moment marks a profound turning point. The Emirati Genome Program, which has already enrolled one million participants and stands as the world’s most comprehensive population genome programme, will now transition from data collection to clinical application. The emphasis shifts deliberately from the laboratory to the bedside, from research to remedy, from understanding genetics in the abstract to harnessing those insights for each individual’s benefit.

At the heart of this transformation lies an audacious commitment: from December 2026, some 900,000 participants will receive personalised genomic reports, the world’s largest initiative of its kind. These documents will contain information spanning 214 inherited genomic conditions and health traits, accompanied by guidance tailored to each person’s genetic profile. The reports will be accessible through the TAMM platform, ensuring that citizens can access these deeply personal health insights with the rigour and confidentiality the moment demands.

The masterplan comprises four pillars, each addressing a different dimension of precision medicine. First, access to the Emirati Genome Program will extend to encompass 100 per cent of Emirati citizens, ensuring that genome sequencing and analysis become a universal foundation for personalised healthcare. Second, those personalised genomic reports will empower individuals to understand their predispositions and take early preventative action. Third, the Newborn Genetic Screening Programme will expand nationwide, covering more than 730 genes linked to more than 815 childhood genetic conditions where early intervention can alter the course of a child’s life. Fourth, the Trusted Research Environment will deepen, providing researchers and healthcare institutions with a secure digital space where artificial intelligence accelerates discovery and innovation.

The Crown Prince emphasised throughout the meeting the imperative to translate research into practice, to move beyond data collection toward tangible improvements in how communities live and thrive. His vision reflects a sophisticated understanding of modern healthcare: that information without application remains inert, and that the true measure of scientific achievement lies in its capacity to enhance quality of life.

Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi and Secretary-General of the Emirates Genome Council, described the masterplan as establishing new standards for genomic implementation at the community level. The convergence of an unprecedented genomic database, artificial intelligence, and a robust regulatory framework creates something novel: the ability to shift from sequencing toward prevention at scale, to offer insights once confined to research into the hands of ordinary citizens living ordinary lives.

As the Crown Prince recently underscored the role of advanced technologies in shaping the nation’s future, this genomics initiative represents that vision made specific: technology not as spectacle, but as the quiet infrastructure of a healthier, more resilient society.

What it means for Abu Dhabi

The masterplan signals a maturation in the UAE’s healthcare ambitions. Where other nations remain in the early stages of genomic medicine, Abu Dhabi will offer its entire citizen population the benefits of precision healthcare informed by comprehensive genetic understanding. This is not marginal improvement but structural transformation: a healthcare system that acts before disease takes hold, that understands the unique genetic landscape of each individual, and that deploys intervention with scientific precision.

For Abu Dhabi’s residents, the implications are profound. The Newborn Genetic Screening Programme’s nationwide expansion means families can identify and treat genetic conditions within the critical first weeks of life. Personalised genomic reports empower adults to make informed decisions about their health trajectories. The Trusted Research Environment, which has already attracted interest from 21 research and healthcare entities globally, positions Abu Dhabi as a nexus of innovation where scientific discovery accelerates. These are not abstract achievements but the architecture of a society that extends longevity and quality of life across its entire population.

Source: WAM